Clinical Trial Update: Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds [Phase 2]

View source ↗

Summary

Phase 2 open-label study of APX001 (fosmanogepix) for invasive mold infections including Aspergillus; the trial was terminated and results were posted in May 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Aspergillosis
• Invasive Fungal Infection

Drugs mentioned

• APX001 (fosmanogepix)

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Invasive Fungal Infections | Phase 2 | Status: TERMINATED | Results posted: 2023-05-19